Resultats de la cerca - David J. Inwards
- Mostrar 1 - 20 resultats de 76
- Anar a la pàgina següent
-
1
-
2
-
3
-
4
-
5
-
6
Early lymphocyte recovery post‐autologous haematopoietic stem cell transplantation is associated with better survival in Hodgkin's disease per Luis F. Porrata, David J. Inwards, Ivana N. Micallef, Stephen M. Ansell, Susan M. Geyer, Svetomir N. Markovic
Publicat 2002Artigo -
7
-
8
-
9
-
10
-
11
-
12
Mucosal CD30-positive T-cell lymphoproliferations of the head and neck show a clinicopathologic spectrum similar to cutaneous CD30-positive T-cell lymphoproliferative disorders per Andrew P. Sciallis, Mark E. Law, David J. Inwards, Rebecca F. McClure, William R. Macon, Paul J. Kurtin, Ahmet Doǧan, Andrew L. Feldman
Publicat 2012Artigo -
13
Awareness and utilization of pre-exposure prophylaxis and HIV prevention services among transgender and non-binary adolescent and young adults per Arianna Rodriguez, Keith J. Horvath, Nadia Dowshen, Raina V. Voss, Jonathan Warus, Megan A Jacobs, Kacie M. Kidd, David J. Inwards-Breland, Jill Blumenthal
Publicat 2024Artigo -
14
Early Lymphocyte Recovery Predicts Superior Survival after Autologous Stem Cell Transplantation in Non-Hodgkin Lymphoma: A Prospective Study per Luis F. Porrata, David J. Inwards, Stephen M. Ansell, Ivana N. Micallef, Patrick B. Johnston, Dennis A. Gastineau, Mark R. Litzow, Jeffrey L. Winters, Svetomir N. Markovic
Publicat 2008Artigo -
15
Testicular lymphoma is associated with a high incidence of extranodal recurrence per Rafaël Fonseca, Thomas M. Habermann, Joseph P. Colgan, Brian Patrick O’Neill, William L. White, Thomas E. Witzig, Kathleen S. Egan, James A. Martenson, Lawrence J. Burgart, David J. Inwards
Publicat 2000Artigo -
16
Long‐term results of the treatment of patients with mantle cell lymphoma with cladribine (2‐CDA) alone (95‐80‐53) or 2‐CDA and rituximab (N0189) in the North Central Cancer Treatme... per David J. Inwards, Paul A. S. Fishkin, David W. Hillman, David W. Brown, Stephen M. Ansell, Paul J. Kurtin, Rafaël Fonseca, Roscoe F. Morton, Michael H. Veeder, Thomas E. Witzig
Publicat 2008Artigo -
17
Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate per MA Gertz, Martha Q. Lacy, Angela Dispenzieri, Stephen M. Ansell, M. A. Elliott, D A Gastineau, David J. Inwards, Ivana N. Micallef, Luis F. Porrata, Ayalew Tefferi, Mark R. Litzow
Publicat 2004Artigo -
18
Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial per Patrick B. Johnston, Betsy LaPlant, Ellen D. McPhail, Thomas M. Habermann, David J. Inwards, Ivana N. Micallef, Joseph P. Colgan, Grzegorz S. Nowakowski, Stephen M. Ansell, Thomas E. Witzig
Publicat 2016Artigo -
19
Quality of life at diagnosis predicts overall survival in patients with aggressive lymphoma per Carrie A. Thompson, Kathleen J. Yost, Matthew J. Maurer, Cristine Allmer, Umar Farooq, Thomas M. Habermann, David J. Inwards, William R. Macon, Brian K. Link, Allison Rosenthal, James R. Cerhan
Publicat 2018Artigo -
20
Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study per Stephen M. Ansell, Hui Tang, Paul J. Kurtin, Patricia Koenig, David J. Inwards, Keith Shah, Steven C. Ziesmer, Andrew L. Feldman, Radha M. Rao, Mamta Gupta, Charles Erlichman, Thomas E. Witzig
Publicat 2011Artigo
Eines de cerca:
Matèries relacionades
Medicine
Internal medicine
Lymphoma
Oncology
Gastroenterology
Transplantation
Surgery
Immunology
Chemotherapy
Biology
Hematopoietic stem cell transplantation
Rituximab
Confidence interval
Genetics
Diffuse large B-cell lymphoma
Physics
Stem cell
Antibody
Cancer
Follicular lymphoma
Autologous stem-cell transplantation
Hazard ratio
Multiple myeloma
Psychology
Cohort
Environmental health
Haematopoiesis
Lymphocyte
Mantle cell lymphoma
Progression-free survival